We are live on ! Find out more
APTO

Aptose Biosciences, Inc.
APTO

Delisted

APTO was delisted on the 1st of April, 2025.

Back to rankings

22 hedge funds and large institutions have $897K invested in Aptose Biosciences, Inc. in 2024 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

4% less funds holding

Funds holding: 23 → 22 (-1)

20% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 5

32% less capital invested

Capital invested by funds: $1.33M → $897K (-$431K)

75% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 4

Holders
22
Holders Change
-1
Holders Change %
-4.35%
% of All Funds
0.29%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
1
Reduced
4
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BL
Bleichroeder LP
New York
+$759K
2
SPC
Sigma Planning Corp
Michigan
+$91.6K
3
HF
HRT Financial
New York
+$13.1K
4
NFG
Nations Financial Group
Iowa
+$5.92K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$776K
2
NCM
Nantahala Capital Management
Connecticut
-$31.8K
3
UBS Group
UBS Group
Switzerland
-$23K
4
Morgan Stanley
Morgan Stanley
New York
-$7.86K
5
TSS
Two Sigma Securities
New York
-$5.78K
Name Holding Trade Value Shares
Change 		Change in
Stake
BL
1
Bleichroeder LP
New York
$563K +$759K +83,333 New
SPC
2
Sigma Planning Corp
Michigan
$158K +$91.6K +10,054 +75%
DS
3
DRW Securities
Illinois
$134K – – –
UBS Group
4
UBS Group
Switzerland
$13K -$23K -2,521 -57%
HF
5
HRT Financial
New York
$9K +$13.1K +1,437 New
AC
6
Annandale Capital
Texas
$6K – – –
Cetera Investment Advisers
7
Cetera Investment Advisers
Illinois
$4.4K – – –
NFG
8
Nations Financial Group
Iowa
$4.39K +$5.92K +650 New
TSS
9
Two Sigma Securities
New York
$2.57K -$5.78K -634 -63%
Morgan Stanley
10
Morgan Stanley
New York
$1.24K -$7.86K -862 -82%
US Bancorp
11
US Bancorp
Minnesota
$455 – – –
GG
12
Gleason Group
Kentucky
$274 – – –
NFSG
13
Newbridge Financial Services Group
Florida
$187 – – –
TWC
14
TD Waterhouse Canada
Ontario, Canada
$154 – – –
Osaic Holdings
15
Osaic Holdings
Arizona
$95 – – –
HWM
16
HighMark Wealth Management
Minnesota
$68 – – –
Northwestern Mutual Wealth Management
17
Northwestern Mutual Wealth Management
Wisconsin
$30 – – –
SS
18
SBI Securities
Japan
$30 +$46 +5 New
Group One Trading
19
Group One Trading
Illinois
$26 – – –
FDCDDQ
20
Federation des caisses Desjardins du Quebec
Quebec, Canada
$23 – – –
CSC
21
Caldwell Sutter Capital
California
$21 – – –
PCWA
22
Pacific Capital Wealth Advisors
California
$1 – – –
SPIA
23
Steward Partners Investment Advisory
New York
$1 – – –
AC
24
Armistice Capital
New York
– -$776K -62,933 Closed
NCM
25
Nantahala Capital Management
Connecticut
– -$31.8K -2,578 Closed
1
2

APTO Hedge Fund Activity: Q4 2024 in Review

22 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Aptose Biosciences, Inc. (APTO) for Q4 2024, worth a combined $897K — down 32% from $1.33M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of APTO and 4 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 1 added.

The largest buyer was Bleichroeder LP, opening a new position worth an estimated $759K. The largest seller was Armistice Capital, exiting entirely with an estimated $776K sold.

  • 22 institutional investors held Aptose Biosciences, Inc. (APTO) as of Q4 2024, down from 23 in Q3 2024.
  • Funds reported $897K of Aptose Biosciences, Inc. stock for Q4 2024, down 32% quarter-over-quarter.
  • 4 funds opened new Aptose Biosciences, Inc. positions in Q4 2024 and 5 closed out, a net change of -1 holder.
  • The largest Aptose Biosciences, Inc. buyer in Q4 2024 was Bleichroeder LP, an estimated $759K added.
  • The largest Aptose Biosciences, Inc. seller in Q4 2024 was Armistice Capital, an estimated $776K sold.

Based on aggregated 13F filings for Q4 2024.